Patents by Inventor Beth Burnside

Beth Burnside has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080050430
    Abstract: A process for treating a bacterial infection with an antibiotic, comprising: administering to a patient with a bacterial infection a product that includes a modified release dosage form containing an antibiotic, said product being administered once-a-day in a dosage and for a number of days that provides a Total T>MIC sufficient to achieve at least the minimum amount of bacterial eradication for treatment of said bacterial infection.
    Type: Application
    Filed: May 7, 2007
    Publication date: February 28, 2008
    Inventors: Henry Flanner, Robert Guttendorf, Donald Treacy, Susan Clausen, Beth Burnside
  • Publication number: 20070134327
    Abstract: Disclosed are once-a-day penicillin-type antibiotic products comprising at least one modified release dosage form comprising penicillin-type antibiotics and pharmaceutically acceptable carriers, which compositions provide T>MIC90 in the serum for at least 5 hours (preferably for at least five consecutive hours), within a 24-hour dosing interval, for a given bacterial pathogen's MIC90, while providing a total dosage of the penicillin-type antibiotic for a 24-hour dosing interval.
    Type: Application
    Filed: December 8, 2006
    Publication date: June 14, 2007
    Inventors: Henry Flanner, Robert Guttendorf, Susan Clausen, Donald Treacy, Beth Burnside
  • Publication number: 20060193908
    Abstract: An extended release pharmaceutical compressed composition and dosage form comprising poorly water soluble macrolide antibiotic, surfactant and non-lipophilic, non-polymeric excipient is disclosed. The composition releases the macrolide antibiotic over an extended period of time, generally at least over 12 hours, even in the absence of a release rate-retarding polymer, release rate-retarding coating or release rate-retarding lipophilic excipient. The composition is suitable for once daily or twice daily oral administration for the treatment of many different types of bacterial infections. One embodiment of the compressed composition includes a drug-containing granular composition and a binding composition, wherein the two are mixed together and then compressed into a tablet or pill. The surfactant is in admixture with or coated onto the macrolide antibiotic, and it can be included in the granular composition and/or the binding composition.
    Type: Application
    Filed: November 4, 2005
    Publication date: August 31, 2006
    Inventors: Beth Burnside, Colin Rowlings, Sandra Wassink, Donald Treacy, John Koleng
  • Publication number: 20060003005
    Abstract: A pharmaceutical tablet comprising an immediate release portion containing an active ingredient and a delayed release portion, wherein the delayed release portion comprises an enteric-coated layer and within the enteric-coated layer there is at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric-coated mini-tablet dosage forms containing an active ingredient, is disclosed.
    Type: Application
    Filed: July 1, 2005
    Publication date: January 5, 2006
    Inventors: Bruce Cao, Sandra Wassink, Donald Treacy, Beth Burnside, Colin Rowlings, John Bonck
  • Publication number: 20050158384
    Abstract: A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients which are substantially the same as that provided by ADDERALL XR® type pulsatile formulations.
    Type: Application
    Filed: January 7, 2005
    Publication date: July 21, 2005
    Inventors: Richard Couch, Beth Burnside, Rong-Kun Chang
  • Publication number: 20050142187
    Abstract: Disclosed are products and methods for improving the plasma profile in a patient being treated with a pharmaceutical active agent that is subject to a limited window of absorption, which products and methods comprise orally administering the active agent in multiparticulate form, such that at least a portion thereof is delivered to the intestine while the patient is in the fed condition.
    Type: Application
    Filed: December 23, 2004
    Publication date: June 30, 2005
    Inventors: Donald Treacy, Henry Flanner, Robert Guttendorf, Beth Burnside
  • Patent number: 6890918
    Abstract: A pharmaceutical composition comprising an inhibitor of angiotensin converting enzyme and neutral endopeptidase, such as sampatrilat, and at least one bioavailability enhancer such as an organic acid, e.g., ascorbic acid. Such a composition has improved systemic bioavailability.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: May 10, 2005
    Assignee: Shire Laboratories, Inc.
    Inventors: Beth Burnside, Rong-Kun Chang, Amir Shojaei
  • Publication number: 20050058708
    Abstract: An antibiotic product is comprised of at least three dosage forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there are two delayed release dosage forms, as well as a delayed sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: September 14, 2004
    Publication date: March 17, 2005
    Inventors: Beth Burnside, Henry Flanner, Colin Rowlings
  • Publication number: 20050048114
    Abstract: An antibiotic product is comprised of at least three dosage forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there are two delayed release dosage forms, as well as a delayed sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: August 20, 2004
    Publication date: March 3, 2005
    Inventors: Beth Burnside, Henry Flanner, Colin Rowlings
  • Publication number: 20050037071
    Abstract: Compositions and methods for making robust pellets that contain a high percentage, by weight, of active drug agent, and which also contain additional components that enhance the absorption and solubility of the active drug agent within the gastrointestinal tract (GI tract) without diminishing the robust nature of the pellet, are disclosed.
    Type: Application
    Filed: August 11, 2004
    Publication date: February 17, 2005
    Inventors: Bruce Cao, Beth Burnside, Sandra Wassink, Matt Baker
  • Publication number: 20050037076
    Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there is a delayed release dosage form, as well as two or more delayed sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: August 12, 2004
    Publication date: February 17, 2005
    Inventors: Beth Burnside, Henry Flanner, Colin Rowlings
  • Publication number: 20050019402
    Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: July 20, 2004
    Publication date: January 27, 2005
    Inventors: Beth Burnside, Henry Flanner, Colin Rowlings
  • Publication number: 20050019401
    Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a sustained release dosage form, and a delayed release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: July 20, 2004
    Publication date: January 27, 2005
    Inventors: Beth Burnside, Henry Flanner, Colin Rowlings
  • Publication number: 20050019403
    Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a delayed release dosage form, and a sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: July 20, 2004
    Publication date: January 27, 2005
    Inventors: Beth Burnside, Henry Flanner, Colin Rowlings
  • Publication number: 20040059002
    Abstract: A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients which are substantially the same as that provided by ADDERALL XR® type pulsatile formulations.
    Type: Application
    Filed: January 29, 2003
    Publication date: March 25, 2004
    Applicant: SHIRE LABORATORIES, INC.
    Inventors: Richard A. Couch, Beth Burnside, Rong-Kun Chang
  • Publication number: 20030096761
    Abstract: A pharmaceutical composition comprising an inhibitor of angiotensin converting enzyme and neutral endopeptidase, such as sampatrilat, and at least one bioavailability enhancer such as an organic acid, e.g., ascorbic acid. Such a composition has improved systemic bioavailability.
    Type: Application
    Filed: April 30, 2002
    Publication date: May 22, 2003
    Applicant: Shire BioChem Inc.
    Inventors: Beth Burnside, Rong-Kun Chang, Amir Shojaei
  • Patent number: 5952004
    Abstract: A pharmaceutical preparation comprising a stable, surface-active emulsion or dispersion of a pharmaceutical agent incorporated into an emulsion (i) having a hydrophobic discontinuous phase of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with pharmaceutical agent is incorporated into a pharmaceutical carrier suitable for oral delivery.
    Type: Grant
    Filed: August 28, 1995
    Date of Patent: September 14, 1999
    Assignee: Shire Laboratories Inc.
    Inventors: Edward Rudnic, John McCarty, Beth Burnside, Charlotte McGuinness, George Belenduik